Validation of an AAV gene therapy designed to complement the loss of TDP‐43 splicing repression for ALS‐FTD

These data support validation of our AAV gene therapeutic strategy to attenuate motor neuron disease, including ALS and potentially extended to other human disorders harboring TDP-43 pathology. Other relevant results, including rescue of motor neurons and extension of life span will be presented.